Toxicological and bio-distribution profile of a GM-CSF-expressing, double-targeted, chimeric oncolytic adenovirus ONCOS-102 – Support for clinical studies on advanced cancer treatment

• Lukasz Kuryk ,

  * E-mail: lukasz.kuryk@targovax.com

  Affiliations Targovax Oy, Helsinki, Finland, ImmunoViroTherapy lab, Division of Pharmaceutical Biosciences & Centre for Drug Research, Faculty of Pharmacy, University of Helsinki, Helsinki, Finland, Department of Virology, National Institute of Public Health–National Institute of Hygiene, Warsaw, Poland

  http://orcid.org/0000-0003-1887-6361

  ⨯
• Lotta Vassilev,

  Affiliation Targovax Oy, Helsinki, Finland

  ⨯
• Tuuli Ranki,

  Affiliation Targovax Oy, Helsinki, Finland

  ⨯
• Akseli Hemminki,

  Affiliations University of Helsinki, Faculty of Medicine, Department of Pathology, Cancer Gene Therapy Group, Helsinki, Finland, Department of Oncology, HUCH, Helsinki, Finland, TILT Biotherapeutics Ltd., Helsinki, Finland

  ⨯
• Aila Karioja-Kallio,

  Affiliation Faculty of Medicine, University of Helsinki, Helsinki, Finland

  ⨯
• Onerva Levälampi,

  Affiliation Faculty of Medicine, University of Helsinki, Helsinki, Finland

  ⨯
• Antti Vuolanto,

  Affiliation Targovax Oy, Helsinki, Finland

  ⨯
• Vincenzo Cerullo,

  Affiliation ImmunoViroTherapy lab, Division of Pharmaceutical Biosciences & Centre for Drug Research, Faculty of Pharmacy, University of Helsinki, Helsinki, Finland

  ⨯
• Sari Pesonen

  Affiliation Targovax Oy, Helsinki, Finland

  ⨯